Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

9.39
+0.02500.27%
Volume:930.83K
Turnover:8.60M
Market Cap:972.03M
PE:-1.79
High:9.50
Open:9.00
Low:8.88
Close:9.37
Loading ...

Intellia Therapeutics Delivers a Q4 Beat

Motley Fool
·
27 Feb

Stock Track | Intellia Therapeutics Soars 8.06% Premarket on Upbeat Q4 Results, Strong Pipeline Progress

Stock Track
·
27 Feb

Intellia Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live
·
27 Feb

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Intellia Therapeutics Q4 Net Income USD -128.898 Million

Reuters
·
27 Feb

Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Collaboration Revenue $12.9M, vs. FactSet Est of $8.6M

MT Newswires Live
·
27 Feb

Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Net Loss $-1.27 a Share, vs. FactSet Est of $-1.33 Loss

MT Newswires Live
·
27 Feb

Intellia Therapeutics Q4 2024 GAAP EPS $(1.27) Beats $(1.36) Estimate, Sales $12.87M Beat $8.53M Estimate

Benzinga
·
27 Feb

Intellia Therapeutics Q4 Basic EPS USD -1.27

THOMSON REUTERS
·
27 Feb

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Intellia Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Reuters
·
25 Feb

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks
·
24 Feb

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

Zacks
·
18 Feb

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Simply Wall St.
·
15 Feb